Study Context
This is one of the first rigorous studies (Randomized Controlled Trial) evaluating the clinical efficacy of an AI therapeutic chatbot delivering CBT.
Lead Author and Institution
Dr. Kathleen Fitzpatrick
Stanford University School of Medicine
Main Results
- Significant reduction in depressive symptoms (PHQ-9) after only 2 weeks of use compared to the control group.
- High engagement: participants interacted with the bot almost daily.
Application in Deuswell
Deuswell's conversational agent utilizes the same CBT restructuring paradigms, augmented by LLM understanding, ensuring clinically safe empathy.
